Physician profile
Chad Stuckey
NPI 1275715880
$5,496.62
in general payments reported to CMS, 2019-2025
46 companies · $738 in 2025
The $738 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,373 · 2020: $467 · 2021: $296 · 2022: $911 · 2023: $897 · 2024: $816 · 2025: $738.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,451.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,450.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $967.19 | 2021-2025 | Botox, Ubrelvy, Qulipta |
| Allergan, INC. | $436.05 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $395.96 | 2019-2023 | |
| Ucb, INC. | $262.12 | 2019-2025 | Fintepla, Briviact, Nayzilam |
| Neurocrine Biosciences, INC. | $255.32 | 2022-2025 | Ingrezza, Ongentys |
| Novartis Pharmaceuticals Corporation | $246.92 | 2019-2024 | |
| Alexion Pharmaceuticals, INC. | $228.26 | 2019-2024 | Ultomiris |
| Ge Healthcare | $176.13 | 2022-2025 | |
| Acadia Pharmaceuticals INC | $172.13 | 2020-2025 | Nuplazid, Daybue |
| Lundbeck LLC | $171.86 | 2019-2025 | Vyepti |
| Amgen INC. | $160.99 | 2019-2022 | |
| Lilly USA, LLC | $151.75 | 2019-2025 | Emgality, Reyvow |
| Teva Pharmaceuticals USA, INC. | $142.41 | 2019-2025 | Ajovy |
| Grifols USA, LLC | $136.14 | 2019-2022 | |
| Pfizer INC. | $132.77 | 2023-2025 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chad Stuckey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.